DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Di Leo A, Jerusalem G, Petruzelka L. et al.
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
J Clin Oncol 2010;
28: 4594-4600
doi:10.1200/JCO.2010.28.8415
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.